Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.41 |
| ▸ | HTR3B | O95264 | 5/20 | 0.41 |
| ▸ | HTR3A | P46098 | 5/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23919754 | 0.86 | PDE10A (0.40) | HRH4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21208611 | 0.85 | HTR3A (0.40) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL21208562 | 0.83 | PDE10A (0.42) | HRH4PDE10A | |
| SCHEMBL21208572 | 0.81 | HRH4 (0.59) | HRH4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21208445 | 0.80 | HTR3A (0.46) | HRH4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21208569 | 0.78 | HTR3A (0.44) | HRH4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21208444 | 0.76 | HRH4 (0.43) | HRH4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21208502 | 0.75 | HTR3E (0.62) | HRH4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21195069 | 0.71 | PARP1 (0.51) | HRH4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL17254978 | 0.71 | TSHR (0.46) | HRH4HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
| US-10975076-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190233422-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975076-B2 | Compositions, uses and methods for making them | BAX, CASP3, CASP7 | HRH4 4472/4885HTR3E 1219/4885HTR3B 1460/4885 |
| US-20190233422-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | HRH4 4546/4885HTR3E 2808/4885HTR3B 2778/4885 |
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, CASP7 | HRH4 4656/4885HTR3E 1936/4885HTR3B 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.